^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation + TP53 mutation + PTEN mutation

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor, TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1, PTEN, Phosphatase and tensin homolog, Mutated In Multiple Advanced Cancers 1, Phosphatase And Tensin Homolog, Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase And Dual-Specificity Protein Phosphatase PTEN, MMAC1, TEP1, MMAC1 Phosphatase And Tensin Homolog Deleted On Chromosome 10, Mitochondrial Phosphatase And Tensin Protein Alpha, Phosphatase And Tensin-Like Protein, Protein Tyrosine Phosphatase, Mitochondrial PTENalpha, PTENbeta, PTEN1, CWS1, GLM2, MHAM
    Entrez ID:
    1956; 7157; 5728
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    10ms
    Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial. (PubMed, Chin Clin Oncol)
    Leveraging the molecular characterization of GBM alongside advancing treatments such as chemoradiation with TTF presents a new opportunity to improve precision oncology and outcomes for GBM patients.
    Clinical data • Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
    |
    MGMT promoter methylation • TERT mutation • TERT promoter mutation • EGFR mutation + TP53 mutation + PTEN mutation
    |
    temozolomide
    1year
    Molecular markers impacting survival in patients receiving concurrent chemoradiation and Tumor-Treating Fields (TTF) in patients with newly diagnosed glioblastoma: secondary analysis of SPARE trial (AAN 2023)
    Background SPARE trial (Scalp-sparing radiation with concurrent temozolomide (TMZ) and tumor treating fields; NCT03477110) is a single-arm pilot study that demonstrated the safety and feasibility of concurrent TTF with chemoradiation for newly diagnosed glioblastomas (GBM)...However, patients with TERT mutations showed improved OS. Due to the small sample size, further validation studies should be conducted.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
    |
    TP53 mutation • EGFR mutation • PTEN mutation • TERT mutation • IDH wild-type • EGFR mutation + TP53 mutation + PTEN mutation • MGMT mutation
    |
    temozolomide
    over1year
    Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer (IASLC-TTLC 2023)
    The inferior outcomes in patients with EGFR-mutant NSCLC with tumors harboring a co-occurring TP53 mutation may be due to additional TSG alterations rather than TP53 mutational status alone. This may have implications for understanding the biologic underpinnings of differential outcomes to EGFR-TKIs.
    Clinical • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1)
    |
    TP53 mutation • EGFR mutation • TP53 wild-type • EGFR mutation + TP53 mutation + ARID1A mutation • EGFR mutation + TP53 mutation + BRCA1 mutation • EGFR mutation + TP53 mutation + NF1 mutation • EGFR mutation + TP53 mutation + PTEN mutation • EGFR mutation + TP53 mutation + RB1 mutation